|
|
|
|
|
 |
LEADERSHIP
|
|
| |
|
|
| |
Samuel E. Lynch, D.M.D., D.M.Sc. is a founder of BioMimetic and has served as President, Chief Executive Officer and a director since its inception. Dr. Lynch served as Chairman of BioMimetic's board of directors from inception until August 2005. Prior to founding BioMimetic, Dr. Lynch spent over four years at Luitpold Pharmaceuticals, Inc., a US subsidiary of Sankyo, Co., Ltd. as Vice President with P&L responsibility for the Osteohealth Co., a division focused on bone and tissue regeneration. Dr. Lynch successfully managed all aspects of the business, including sales, marketing, clinical development and G&A functions, resulting in a "turn-around" and conversion into a highly profitable business. Prior to joining Sankyo – Luitpold, Dr. Lynch was the Executive Director for Research and Development for the Institute of Molecular Biology, a private research institute affiliated with Harvard University, where he directed research in bone and tissue healing. He concurrently served on the faculty at Harvard School of Dental Medicine for six years, from which he earlier received a Certificate of Specialty in Periodontology. Dr. Lynch also received a Doctorate of Medical Sciences from the Harvard Medical School. In addition to his industry success, Dr. Lynch has a long record of scientific accomplishments, has published and lectured extensively and is a co-inventor of BioMimetic's technologies. |
| |
William Beasley is Director, Clinical Affairs. He previously served five years in clinical trials management at Covance, Inc., a large, multinational Clinical Research Organization (CRO) where he directed phase I - phase III clinical trials for major international pharmaceutical companies. In his current position, Mr. Beasley successfully conducted the pivotal trial on GEM 21S. He has implemented an electronic data capture (EDC) instrument developed by a small CRO into the company's clinical program, substantially improving clinical trial efficiencies. Mr. Beasley's clinical research management experience includes a diverse range of pharmaceuticals, biologics, medical devices and combination products in multiple therapy areas. |
| |
Larry Bullock joined BioMimetic in January 2004 as Chief Financial Officer. From January 1996 to February 2003, Mr. Bullock served as Chief Financial Officer of Ribozyme Pharmaceuticals Inc., now called Sirna Pharmaceuticals Inc., and as Chief Financial Officer of La Jolla Pharmaceuticals for five years prior to joining Sirna. He led both companies through their private to public transitions, completing private and initial public offerings and building the public reporting team. Mr. Bullock received his M.B.A. from the University of Utah and his B.A. from Indiana University. |
| |
Earl Douglas, Esq. joined BioMimetic in May 2005 as General Counsel. Mr. Douglas has been a practicing attorney for almost 20 years and has a strong background in intellectual property law. Mr. Douglas served as Vice President and General Counsel of Spinal Dynamics Corporation from December 2001 to December 2002 and as Chief Patent Counsel from October 2000 to December 2001. Mr. Douglas was an intellectual property attorney for Smith & Nephew, Inc. from July 1995 to October 2000. Mr. Douglas received his J.D. from Columbia University and his B.S. in chemical engineering from the Massachusetts Institute of Technology.
|
| |
Charles E. Hart, Ph.D. joined BioMimetic in January 2004 as Chief Scientific Officer and Vice President. Prior to joining BioMimetic, he spent 21 years at ZymoGenetics, Inc., a biotechnology company focused on therapeutic proteins, where he held a variety of positions, including Senior Director of Corporate Communications and Investor Relations, Senior Director of Business Development, and Director of Protein Biochemistry. He is the author of over 50 scientific publications and holds 20 US patents, the majority of which are related to PDGF. Dr. Hart received his Ph.D. from the University of Washington, his M.S. from Oregon State University and his B.S. from the University of California at Davis. He currently holds the position of Affiliate Assistant Research Professor in the Department of Pathology at the University of Washington. |
| |
Steve Hirsch joined BioMimetic in July 2005 as Executive Vice President, Orthopedics and Chief Operating Officer. From October 1996 to June 2005, Mr. Hirsch served in various positions in the Orthopedics Division of London-based Smith & Nephew, plc. His responsibilities at Smith & Nephew included responsibilities in the marketing and sales areas. From January 2003 to February 2005, Mr. Hirsch was the Senior Vice President and General Manager of the Reconstructive (total joint) Division of the orthopedics business. His last position with Smith & Nephew was President of the European Orthopedic business, with annual revenues in excess of $200 million. Mr. Hirsch spent 24 years in the orthopedic device industry, first with the Howmedica Division of Pfizer, Inc. where he held a variety of positions including Vice President of Sales and Marketing for the US Orthopedics business. Mr. Hirsch received a B.E.Sc. from the Johns Hopkins University and a M.S.I.A. from the Krannert School of Business at Purdue University. |
| |
John McKay joined the Company effective September 28, 2007 and holds the position of Vice President, Quality and Environmental, Health, Safety (EHS). Mr. McKay brings 22+ years of international experience in the fields of Quality, EHS, Operations, Engineering, Compliance, Training, Integrated Auditing, Maintenance/Reliability and Product Development programs to BMTI. Most recently he served as Senior Director, Compliance at Stryker Physiotherapy Associates where he led the systems for healthcare quality, compliance and Corporate Integrity Agreement, and assured compliance with regulatory, ethics, code of conduct and company policies. Prior to that, he held several senior management positions within the Bayer Corporation, including Manager, Operational Excellence, leading global efforts for performance improvement, ISO standards, quality, management systems, and integrated auditing. He also spent 15 years at Lyondell, ARCO Chemical Company, Rohm and Haas Company where he held various global management positions in Manufacturing Excellence, Operational Excellence, Quality Assurance, Quality Control, EHS, Operations, Product Development, Engineering, Training, Supply Chain Management, Plant Management, Maintenance/Reliability, and Integrated Auditing. Mr. McKay received his B.S. in Chemical Engineering from Pennsylvania State University and is a graduate of the University of Pennsylvania Business School's Wharton Management Program. Mr. McKay holds several Quality, Environmental and Safety/Health certifications. His experience includes Pharmaceuticals, Medical Devices, Specialty/Intermediate Chemicals, Petrochemicals, and Contract Manufacturing. |
| |
James Monsor is Vice President, Operations. Mr. Monsor spent 15 years in positions of increasing responsibility at Abbott Laboratories within operations and quality. Most recently, he was Director of Product Supply for ALK-Abello, where he was responsible for the entire product supply chain for US operations. He has had responsibility for all aspects of supply chain management, quality assurance, quality control, regulatory affairs, customer service, facilities management, construction management, and HR. His experience includes Aseptic Processing, Medical Devices, and Bulk Pharmaceuticals. |
| |
Russ Pagano, Ph.D. joined the Company effective May 23, 2007 in the position of vice president of regulatory and clinical affairs. Dr. Pagano received his Ph.D. from Duke University and joined the US Food and Drug Administration ("FDA") as a scientific reviewer in the Office of Device Evaluation in 1994. He served as FDA chief of the Restorative Devices Branch, which included a portion of the organization's orthopedic products from 1997 to 2000 and FDA chief of the Pacing, Defibrillators and Leads Branch from October 2000 to May 2001. Since that time, he has been executive vice president and regulatory advisor at M Squared Associates, a consulting firm in Washington D.C. In that capacity, Dr. Pagano served as a regulatory consultant to BioMimetic and numerous other companies. |
| |
Leo Snel joined BioMimetic in August 2007 as Vice President of R&D Protein Biochemistry. He brings 30 years of protein science and product development expertise to BMTI, most recently at Amgen leading a Global Operations team to launch Amgen's first Oncology protein therapeutic. Prior to that Mr. Snel spent two years at ZymoGenetics as Senior Director of Analytical Sciences and Contract Manufacturing, and 24 years at Novo Nordisk where he held a variety of positions, including 6 years as Director of Biologics Development for the Health Care Division. Leo Snel received his MSc from the Technical University of Denmark and a Diploma in Drug & Device Development from the Scandinavian International Management Institute. |
| |
|
|
| |
 |
|
|
| |
| |
|
|
|
|
|
|
